Refine by
In Vivo Model Suppliers & Manufacturers
44 companies found
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Erucin (ERU) is an isothiocyanate particularly abundant in arugula. Erucin shows anticancer, neuroprotective, and anti-inflammatory ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
based inLondon, UNITED KINGDOM
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, ...
based inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon ...
based inAtlanta, GEORGIA (US) (USA)
Lena Biosciences, Inc. was established in 2008 with a goal of improving cell culture techniques by providing a more physiologically relevant method to predict human outcomes. In 2010, our SeedEZ 3D cell culturing scaffold was conceived allowing ...
based inSan Francisco, CALIFORNIA (USA)
Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. A key application is Prellis’ Externalized Immune System, EXIS, which through the creation of lymph node ...
EXIS Human Immune Response: Prellis utilizes its proprietary holographic printing technology to engineer 3D printed lymph node organoids (LNOs) that recreates the human immunobiology in vitro allowing direct access to a fully functional human immune ...
based inBoston, MASSACHUSETTS (USA)
Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease. We support our clients to achieve more in their target & biomarker programs. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight ...
We are developing novel causal artificial intelligence and machine learning (AI/ML) and unconventional computing strategies to better understand human biology – and then apply these to deliver better medicine and improve health for people ...
based inAustin, TEXAS (USA)
vivoVerse, Inc., formerly operating as Newormics LLC, develops and manufactures advanced microfluidics, automation, and AI/ML technologies to rapidly and ethically test toxicology/safety profiles of chemicals using C. elegans as a New Approach ...
C. elegans is recognized as a useful alternative in vivo model. The vivoChip® enables the use of C. elegans for high-content, multi-parametric analysis of neurodegeneration phenotypes from high-resolution ...
based inAbingdon, UNITED KINGDOM
Founded on innovation and operating with an entrepreneurial flair, Oxford Optronix is a global pioneer in design, development and manufacture of sophisticated instrumentation for the life sciences. Our products are designed, developed and ...
based inAudubon, PENNSYLVANIA (USA)
Globus Medical is a leading medical device manufacturer with the goal of improving the quality of life for patients with musculoskeletal disorders. We are inspired by the needs of these patients and by the surgeons and healthcare providers who treat ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
The nematode Caenorhabditis elegans is widely used in genetic and biomedical research. DNA fragment insertions can be introduced into the C. elegans genome. Our C. elegans knock-in services include point mutations, floxed alleles, degron tagging, ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Acuitas is a private company based in Vancouver, British Columbia and was founded in February 2009. We are partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the ...
Acuitas specializes in the development of lipid nanoparticle delivery systems for molecular therapeutics. Our scientists have synthesized over 500 novel cationic lipids which have been evaluated in in vivo ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
There are two XF-73 dermal programmes in development. One is being run by our China partner and shareholder – China Medical Systems Holdings Limited (CMS) – focused on superficial skin infections and the other is an in-house programme ...